See more : Euglena Co., Ltd. (2931.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nexien BioPharma, Inc. (NXEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nexien BioPharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Festi hf. (FESTI.IC) Income Statement Analysis – Financial Results
- PHP Ventures Acquisition Corp. (PPHPR) Income Statement Analysis – Financial Results
- AGNC Investment Corp. (4OQ1.F) Income Statement Analysis – Financial Results
- CITBA Financial Corporation (CBAF) Income Statement Analysis – Financial Results
- Industrial and Commercial Bank of China Limited (IDCBF) Income Statement Analysis – Financial Results
Nexien BioPharma, Inc. (NXEN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.nexienbiopharma.com
About Nexien BioPharma, Inc.
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.86K | 116.79K | 73.46K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 282.61K | 563.99K | 1.84M | 2.64M | 3.87M | 1.17M | 185.20K | 16.35K | 46.68K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 |
| SG&A | 155.66K | 282.61K | 563.99K | 1.84M | 2.64M | 3.87M | 1.17M | 185.20K | 16.35K | 46.68K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.64K | 1.77K |
| Operating Expenses | 155.66K | 282.61K | 563.99K | 1.84M | 2.64M | 3.93M | 1.28M | 258.65K | 16.35K | 48.44K |
| Cost & Expenses | 155.66K | 282.61K | 563.99K | 1.84M | 2.64M | 3.93M | 1.28M | 258.65K | 16.35K | 46.68K |
| Interest Income | 0.00 | 79.29 | 62.37 | 16.18 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.45K | 79.29K | 62.37K | 16.18K | 33.00 | 0.00 | 0.00 | 5.84K | 4.64K | 1.77K |
| Depreciation & Amortization | 0.00 | 282.61K | 563.99K | 1.84M | 2.64M | 3.93M | 1.28M | 765.73K | 4.64K | 1.77K |
| EBITDA | -155.66K | -282.61K | 0.00 | -1.84M | 0.00 | -367.92K | 0.00 | 0.00 | -16.35K | -46.68K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -155.66K | -282.61K | -563.99K | -1.84M | -2.64M | -3.57M | -1.28M | -258.65K | -16.35K | -48.44K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -83.45K | -79.29K | -62.37K | -16.18K | -35.03K | -735.83K | 0.00 | -507.08K | -4.64K | -1.77K |
| Income Before Tax | -239.11K | -361.90K | -626.36K | -1.86M | -2.67M | -4.30M | -1.28M | -258.65K | -20.99K | -48.44K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -239.11K | -282.61 | -563.99 | 16.18K | 33.00 | 735.83K | -1.28M | -765.73K | -22.82K | 0.00 |
| Net Income | -239.11K | -361.90K | -626.36K | -1.88M | -2.67M | -5.04M | -1.28M | -258.65K | -20.99K | -48.44K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.03 | -0.05 | -0.10 | -0.03 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.03 | -0.05 | -0.10 | -0.03 | -0.01 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 66.19M | 62.33M | 57.86M | 55.40M | 53.91M | 51.03M | 42.67M | 24.11M | 3.79M | 22.71M |
| Weighted Avg Shares Out (Dil) | 66.19M | 62.33M | 57.86M | 55.40M | 53.91M | 51.03M | 42.67M | 24.11M | 3.79M | 22.71M |
Source: https://incomestatements.info
Category: Stock Reports